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A twenty-two year old female patient presented 
with new onset bilateral hard orbital masses and 
progressively worse tear lake problems. Computed 
tomography of the orbits revealed poorly differentiated 
bilateral orbital masses. Laboratory investigation 
revealed ANCA positivity.  Routine biochemical 
investigations were all within normal limits. CXR was 
also normal. Biopsy of the orbital masses revealed non-
specific histological findings. An initial diagnosis of 
Granulomatosis with Polyangitis (GPA) was postulated. 
Oral steroids were given followed by a rapid response to 
steroid therapy. The working diagnosis of GPA was 
abandoned and a diagnosis of idiopathic orbital 
inflammation (IOI), or orbital pseudotumour was made 
owing to the benign, non-infective, inflammatory 
pathology with no evident systemic or local cause.  
Tailoring off of steroids resulted in repeated flare ups, 
resulting in the initiation of methotrexate therapy. The 
patient is in remission and is currently on combined 
steroid and methotrexate treatment. IOI is a diagnosis of 
exclusion and a rapid response to steroids serves as a 
diagnostic aid but is not in itself diagnostic. 
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Idiopathic orbital inflammation (IOI) or orbital 
pseudotumour is an uncommon, benign, non-infective, 
inflammatory pathology involving the orbital tissues. 
It is a diagnosis of exclusion after systemic and local 
causes have been thoroughly excluded, characterised 
by polymorphous lymphoid infiltrate with varying 
degrees of fibrosis. MR orbit is the single most 
important investigation. A diagnosis is usually 
clinched when a rapid response is seen to oral or 
systemic steroids. The pathological process 
underlying IOI remains unresolved, some postulating 
it is primarily an autoimmune process.  
 
Case Presentation  
A twenty-two year old female patient presented 
with bilateral orbital masses and persistent tear lake 
problems. There was associated proptosis but no 
involvement or impairment of any of the extra-ocular 
muscles movements.  Humphrey Visual Field 
examination did not reveal any visual field defect.  
There was an extremely toxic tear lake secondary to 
the severe dacryoadenitis spilling inflammatory debris 
onto the front of the eye.  
Masses were present in both lacrimal glands, 
especially on the right side, spilling down into the 
inferior part of the right orbit. Masses were woody 
hard with gross inflammation of the ocular surface 
overlying it. There was no corneal guttering or 
scleritis. 
Serial MR Orbits were performed. The first 
revealed significant right preseptal and post-septal 
orbital change, which appeared to include and 
emanate from the region of the right lacrimal gland. 
The left lateral gland also appeared mildly prominent.  
A biopsy of the right lower orbital mass revealed 
fibroconnective tissue with a patchy chronic 
inflammatory infiltrate and no identifiable fat. The 
infiltrate included ill-formed lymphoid-follicles and a 
loose scattering of lymphocytes and histiocytes with 
only rare plasma cells and eiosinophils.  Occasional 
multinucleate giant cells were seen. There was no 
frank necrosis but ample nuclear dust was visible. 
There was no vasculitis and no evidence of underlying 
neoplasia. Findings were deemed to be non-specific 
but likely to be due to Granulomatosis with 
Polyangitis (GPA). 
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Laboratory investigation revealed elevated 
ANCA titres. Further breakdown of such titres 
revealed elevated P-ANCA patterns with grossly 
elevated Anti-Myeloperoxidase but insignificant Anti-
protease 3 antibody levels. CRP, ESR, C3, C4 and 
anti-nuclear antibodies were never elevated and were 
always found within normal limits.  
CXR revealed no evidence of pulmonary 
pathology. 
The patient was started on IV steroids followed 
by oral steroids as an initial diagnosis of GPA was 
suspected. Rapid response to steroids was seen in the 
form of radiological and symptomatic improvement. 
Due to the non-specific histological findings and lack 
of systemic involvement, a diagnosis of GPA was 
abandoned and a diagnosis of IOI was adhered to. 
 
Investigations  
Routine laboratory and haematological 
investigations were normal including serum ACE, T3, 
T4 and TSH. CXR performed revealed no pathology. 
Serum ANCA levels were elevated. Further 
breakdown of such titres revealed P-ANCA patterns 
which are indicative of Anti-Myeloperoxidase 
antibody at 42.4, while Anti-protease 3 antibody was 
less than 2.0.  
Imaging modalities used included computed 
tomography (CT) and magnetic resonance imaging 
(MRI). Usually, CT is the preferred imaging modality 
in IOI because of its good inherent contrast of orbital 
fat, muscle, bony structures and adjacent paranasal 
sinuses. MRI showed diffuse involvement of the 
lacrimal glands with associated infiltration of orbital 
fat. There were bilateral poorly-defined orbital 
masses. Both pre-septal and post –septal changes were 
seen. On T2-weighted imaging areas were 
hypointense in appearance with restricted diffusion. 
Such infiltrative changes favoured a diagnosis of IOI. 
A decision was made to opt for a second opinion 
from specialists at the Moorfield’s Eye Hospital 
London. A decision was made to perform biopsies of 
the left orbital mass in order to exclude an underlying 
malignancy or possible GPA, after the images form 
the MRI performed at Mater Dei Hospital were 
reviewed.    Biopsy is not usually indicated for IOI but 
serves as a good diagnostic tool if a diagnosis has not 
been concretely established. Unfortunately, the 
histopathological spectrum of IOI is typically 
nondiagnostic.  
 
Differential Diagnosis  
IOI is diagnosed by a thorough clinical history 
and evaluation to rule out other causes of orbital 
disease. One must take note of similar episodes in the 
past and the onset of symptoms. Symptoms are rather 
acute in IOI but generally more subacute or chronic in 
other pathologies. Trauma, infection and risk factors 
for immunological compromise must be excluded.  
Infection was considered. The orbit is a common 
site for specific infections, usually spreading from 
adjacent sinuses or the face. It may also be a result of 
direct trauma. The patient was afebrile and routine 
investigations were unremarkable.  
Thyroid orbitopathy must also be excluded. 
Laboratory investigations including T3, T4 and TSH 
were unremarkable. Onset of symptoms was rather 
acute, while in Graves’ disease, a slower, more 
insidious course is usually apparent.  Examination did 
not reveal any eye lid retraction, eyelid lag, extra-
ocular myopathy. There was a mild element of 
proptosis. Radiological findings however were not 
consistent with thyroid orbitopathy. There was no 
evident enlargement of extraocular muscles, while 
conversely, orbital fat volume was reduced.  
Wegener’s Granulomatosis or Granulomatosis 
with polyangitis (GPA) was initially diagnosed 
secondary to the elevated serum ANCA levels. GPA is 
a necrotising granulomatous inflammation and 
vasculitis, effecting the respiratory and renal systems. 
Ophthalmic symptoms are usually acute in onset and 
may be unilateral or bilateral. Systemic work-up of 
our patient revealed no impairment of pulmonary or 
renal function. Further breakdown of ANCA levels 
revealed a grossly elevated P-ANCA level reactive 
against myeloperoxidase while a c-ANCA level 
reactive against proteinase 3 which was within normal 
limits. The anti-Proteinase3: Myeloperoxidase ratio 
was not elevated, making the serum ANCA level 
testing non-diagnostic. Furthermore, radiological 
changes were not classical of GPA, bar the mass 
lesions bilaterally. That being said, classical findings 
of GPA are present in less than a third of patients 
while ANCA is only found in 50-65% of patients with 
the limited form of GPA. A diagnosis of GPA was 
abandoned but ultimately could not be completely 
excluded. 
The possibility of neoplasm must also be 
considered. Although this was excluded at biopsy. 
 
Treatment  
Corticosteroids are usually the mainstay of 
treatment usually providing rapid improvement of 
symptoms.  
Such was the case with our patient. IV steroids 
were initiated after the biopsy was performed. IV 
steroids were given for 2 days followed by oral 
steroids, starting at a dose of 80mg per day, tailoring 
down accordingly over several months. Prednisolone 
treatment was stopped completely after 17 months. 
There was a significant resolution in both symptoms 
and radiological evidence. Methotrexate once weekly 
and 10mg Folic Acid daily were started after 
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prednisolone was stopped. 
The patient is currently still on methotrexate and 
undergoing regular follow up blood investigations. 
She is symptom free but occasionally still suffers 
from flare ups, consisting of orbital pain, a sensation 
of heaviness and conjunctival injection. Flare ups are 
less frequent and less severe ever since the prolonged 
use of methotrexate.  
 
Outcome and Follow-up   
Recurrence rates are high. Regular patient follow 
up is necessary to assess disease progression as well 
as treatment efficacy. Steroid therapy should be 
accompanied by close monitoring to assess for steroid 
related complications.  
Stopping steroids typically results in a relapse 
rate of 60-80%, irrespective of the initial response to 
steroids. Response to steroids at relapse is typically 
not as dramatic as the initial response, commonly 
resulting in the use of other agents. 
In our patient, follow up revealed near complete 
regression of masses bilaterally, with some residual 
disease on the right eye. There was no progression of 
orbital fat infiltration. 
  Serum ANCA levels also showed regression on 




Idiopathic orbital inflammation (IOI) is a non-
malignant, non-infectious orbital inflammation with 
no local or systemic cause. The disease may be 
confined to a single orbital structure, but more 
commonly effects multiple structures.1 Any structure 
may be effected, with orbital fat, lacrimal glands and 
extraocular muscles being most commonly effected.2 
Onset is usually unilateral and acute, progressing 
over a few hours or days. That being said, bilateral 
disease is not uncommon and onset may be subacute 
or even chronic.3 There is no gender, age or racial 
predilection, presenting universally with a mixture of 
infiltrative and inflammatory signs and symptoms.4 
Examination may reveal proptosis, chemosis, 
tenderness, peri-orbital swelling and impaired extra-
ocular muscle function. Ultimately, presentation 
varies depending on the location and degree of 
inflammation, fibrosis or mass effect. 5 
The pathogenesis of IOI remains elusive and 
unclear. An immune-mediated response has been 
implicated as the most likely underlying cause.  
Infectious aetiologies have also been implicated, most 
commonly upper respiratory tract infections and 
Streptococcal pharyngitis. IOI is also strongly related 
to several rheumatological conditions including 
Crohn’s disease, ankylosing spondylitis, rheumatoid 
arthritis, systemic lupus erythematosis and myasthenia 
gravis.6 
Laboratory investigation is usually followed by 
imaging studies. Classically, orbital pseudotumours 
may present as diffuse or localised orbital masses 
which is classically poorly demarcated and enhancing 
with contrast. The lacrimal gland is the most 
commonly involved structure usually showing diffuse 
enlargement with poorly defined margins. Other CT 
findings include diffuse infiltration of orbital fat, 
extraocular muscle enlargement, uveoslceral 
thickening and optic nerve thickening.7 MRI is more 
valuable in demonstrating soft tissue changes in IOI 
(Figure 1, Figure 2). T1 – weighted images show 
intense contrast enhancement of abnormal soft tissues.  
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Figure 2: MR Orbit; Coronal Stir sequence showing regression of orbital inflammation with some residual disease in the 

















It is not uncommon that as a result of diagnostic 
uncertainty, a biopsy is performed. Classical IOI 
reveals an atypical histopathology with a fibro-
inflammatory infiltrate.2 
Before treatment is started, a thorough work up is 
required. If the work up in negative, treatment for 
presumed IOI may be initiated. In some patients, 
symptoms and signs may resolve spontaneously.5 In 
patients with mild clinical presentation, clinical 
progression may be monitored and non-steroidal anti-
inflammatories may be started. In more moderate and 
severe disease, systemic corticosteroids are the 
cornerstone of management.3 Typically, 75% of 
patients show improvement of symptoms and 
radiological findings within 24-72 hours of imitating 
treatment. Steroids must be given for several months 
to ensure remission, ideally starting with a dose of 1-
1.5 mg/kg body weight for 1-2 weeks followed by a 
gradual tapering down of the overall systemic dose. 
A rapid response to steroids, although a useful 
diagnostic indicator, is not diagnostic. Several studies 
have shown steroid unresponsive IOI. Furthermore, 
even with treatment, 23% to 56% of patients tend to 
suffer recurrences, most commonly in cases showing 
bilateral disease. Recurrence is most likely the result 
of incomplete resolution of the initial presentation, 
typically resurfacing when treatment is tapered off. 
 Unfortunately, in cases which are refractory to 
both corticosteroids and radiation therapy, further 
treatment options are limited. Chemotherapeutic 
agents such as cyclophosphamide, cyclosporine or 
methotrexate have proven to be helpful.3 
Following treatment, good visual prognosis may 
be expected. Response and recurrence rates are 
dependent on the degree of inflammation, dose and 
duration of corticosteroid treatment and ultimately the 
natural history of the disease. The clinical and 
histological features do not correlate well with the 
final outcome.1  
 
Patient’s perspective 
The initial period was characterized by anxiety. 
The diagnosis was not certain and neither was the 
approach that was to be taken. The need for review by 
foreign specialists only increased her anxiety and did 
not help in what had been already difficult period. 
 Once a diagnosis was made, there was still 
uncertainty as to the possible response to therapy. She 
was pleased that steroid proved to be very successful 
initially but was left very frustrated by the fact that 
flare-ups did occasionally recur, even though they 
were not as severe as the initial presentation. A 
decision was made to start further treatment in the 
form of methotrexate. This was initially met with 
further anxiety as doubt on the certainty of the 
diagnosis began to resurface. However with 
reassurance and eventual stable response to the 
methotrexate, anxiety was resolved and she no longer 
has any issues with her treatment and response.  
Learning Points/Take Home Messages  
1. IOI is a diagnosis of exclusion.  
2. Thorough history and examination is necessary in 
order to exclude concrete differential diagnosis. 
3. Misdiagnosis may have serious implications 
considering the benign nature of this disease. 
4. A rapid response to steroids serves as a 
diagnostic aid but is not in itself diagnostic.  
5. Investment and research is needed to more 
accurately diagnose IOI. Currently, histological 
features are non-diagnostic, showing 
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